Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401193 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of XP12B in Women With Menorrhagia
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT00401193 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 304 participants.
The verdict
NCT00401193, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
Interventions
- DRUG Tranexamic acid tablets
- DRUG Placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401193
The ClinicalTrials.gov registry entry for NCT00401193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tranexamic acid tablets is the first listed.
NCT00401193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401193 about?
NCT00401193 is a clinical study titled "Efficacy and Safety of XP12B in Women With Menorrhagia". The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
What is the current status of trial NCT00401193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2006-11. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00401193?
The interventions under investigation include: Tranexamic acid tablets (DRUG), Placebo tablets (DRUG).
Who is sponsoring clinical trial NCT00401193?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.